Autoreceptors

Transmitter receptors on or near presynaptic terminals (or varicosities) which are sensitive to the transmitter(s) released by the terminal itself. Receptors for the hormones released by hormone-releasing cells are also included.

Also Known As:

Networked: 233 relevant articles (9 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hamon, Michel: 4 articles (12/2008 - 05/2003)
2.	Mann, J John: 3 articles (07/2013 - 05/2004)
3.	Renoir, Thibault: 3 articles (01/2013 - 12/2008)
4.	Lanfumey, Laurence: 3 articles (01/2013 - 12/2008)
5.	Adrien, Joëlle: 3 articles (01/2006 - 05/2003)
6.	Parsey, Ramin V: 2 articles (07/2013 - 03/2013)
7.	Huang, Yung-Yu: 2 articles (07/2013 - 03/2013)
8.	Ogden, R Todd: 2 articles (07/2013 - 03/2013)
9.	Galligan, James J: 2 articles (04/2013 - 04/2004)
10.	Pang, Terence Y C: 2 articles (01/2013 - 03/2012)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 06/01/2005 - "The aim of this study was to investigate the association between schizophrenia and the G861C polymorphism in the 5-HT1D(beta) autoreceptor gene. " 07/01/2004 - "The aim of the present study was to examine genetic association between schizophrenia and polymorphisms in the 5-HT1Dalpha (TaqI) and 5-HT1Dbeta (T261G and G861C) autoreceptor genes in ninety trios from Portugal. " 07/01/2004 - "Lack of association or linkage disequilibrium between schizophrenia and polymorphisms in the 5-HT1Dalpha and 5-HT1Dbeta autoreceptor genes: family-based association study." 07/01/1991 - "Following pharmacological findings in animal studies, it was postulated that a hyperactivity of dopaminergic neurons, which is possibly present in acute schizophrenia, may be reduced by autoreceptor stimulation. " 01/01/2014 - "Based on the findings on drug-naïve and drug-free patients, it may be hypothesized that schizophrenia initially is characterized by an impaired mechanism of D2 autoreceptor and heteroreceptor sensitization leading to sensitization instead of desensitization in response to increased levels of neostriatal DA. "
2.	Seizures (Seizure) 03/10/2010 - "Hippocampal sst(1) receptors are autoreceptors and do not affect seizures in rats." 01/11/2006 - "The enhanced autoreceptor function may contribute to seizure susceptibility and epileptogenesis in temporal lobe structures." 08/01/1986 - "The degree of protection, however, depends on the dose; therefore, it also is supposed that amphetamine in low doses acts on the autoreceptors with a presynaptic effect, which in this case is protective against the convulsions without affecting the respiration." 01/01/1987 - "Partial protection against hyperbaric oxygen induced convulsions by dopaminergic agents in mice: possible involvement of autoreceptors?" 02/01/1998 - "[3H]5-HT uptake and its release as well as the 5-HT1B autoreceptor function did not differ from shams in hippocampal synaptosomes at stages 2 and 5. Systemic administration of 100 and 1,000 microg kg(-1) 8-OH-DPAT or 1,000 microg kg(-1) WAY-100,635, 30 min before each electrical stimulation, did not significantly alter kindling progression or the occurrence of stage 5 seizures in fully kindled rats. "
3.	Dyskinesias (Dyskinesia) 03/01/2012 - "Here, we review the evidence for serotonergic involvement in dyskinesias from animal and human data, and highlight some of the translational gaps which may explain why the success of serotonin autoreceptor agonists as anti-dyskinetic agents in experimental models has failed to be replicated in clinical trials." 01/01/1988 - "The suppression of neuroleptic-induced persistent abnormal movements by 3-PPP enantiomers may be related to their ability to act as autoreceptor agonists, while the acute motor signs produced by higher doses of (+)-3-PPP may be due to activation of postsynaptic DA receptors. " 01/01/1983 - "Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias." 05/01/1995 - "The pattern of the quinpirole response in reserpine-treated monkeys suggested that the impairments in delayed response and fine motor performance resulted from drug actions at D2 autoreceptors, while the improvement in delayed response performance, dyskinesias and "hallucinatory-like" behaviors resulted from actions at postsynaptic receptors. " 08/01/2005 - "If 5-HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. "
4.	Mood Disorders (Mood Disorder) 04/01/2008 - "It is well established that D3Rs, acting as autoreceptors, inhibit DA synthesis and release, although lack of selective compounds have limited the progress in understanding D3Rs role in mood disorders. " 01/01/2014 - "Specifically, chronic stress significantly attenuates 5-HT neurotransmission and 5-HT1A autoreceptor sensitivity, and this effect could represent an endophenotypic hallmark for mood disorders. " 02/01/2012 - "The serotonin 1A (5-HT(1A)) autoreceptor is known to play a role in mood disorders and their treatments. " 03/01/2011 - "Serotonin (5-hydroxytryptamine, 5-HT) neurotransmission is negatively regulated by 5-HT1A autoreceptors on raphe neurons, and is implicated in mood disorders. " 05/01/2007 - "Based on these data, one may speculate that the 5-HT autoreceptor antagonist/5-HT transport inhibitor SB-649915-B will have therapeutic efficacy in the treatment of affective disorders with the potential for a faster onset of action compared to current selective serotonin reuptake inhibitors."
5.	Overactive Urinary Bladder (Overactive Bladder) 06/01/2014 - "These results indicate that activation of 5-HT1A autoreceptors on the serotonergic neurons in the raphe nucleus may suppress duloxetine and PNS inhibition, suggesting that the coadministration of a 5-HT1A antagonist drug might be useful in enhancing the efficacy of duloxetine alone and/or the additive effect of PNS-duloxetine combination for the treatment of overactive bladder symptoms. "

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Autoreceptors
3.	5-HT1A Serotonin Receptor
4.	Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
5.	Antipsychotic Agents (Antipsychotics)
6.	Reserpine (Serpasil)
7.	Adrenergic Receptors (Adrenergic Receptor)
8.	Amphetamine (Amfetamine)
9.	Serotonin 5-HT1 Receptor Antagonists
10.	Muscarinic M1 Receptor

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Chemical Sympathectomy
4.	Injections
5.	Induced Hypothermia